Webcasts & Presentations
Periocically Resverlogix will webcast from selected conferences/events. Active links will be posted here.
February 14, 2017: BIO CEO & Investor Conference: PDF Presentation
February 2, 2017: Keystone Symposia: Epigenetics and Human Disease: Progress from Mechanisms to Therapeutics, Seattle, WA. PDF of Abstract.
January 9, 2017: 9th Annual Biotech Showcase Conference: PDF Presentation
2016 Research & Development Update for apabetalone (RVX-208) in New York City. Webcast can be accessed by clicking HERE
Research & Development Update
Unmet Need in Diabetes and CVD & RVX MACE Analysis - Prof. Kausik Ray
Apabetalone: Current Research and Development - Ewelina Kulikowski, BSc, PhD
BETonMACE Clinical Update - Michael Sweeney, MD
Unmet Need in CKD & RVX MACE Analysis - Kamyar Kalantar-Zadeh, MD, PhD
Market Opportunity and Concluding Remarks - Donald J. McCaffrey, President & CEO
September 14th, 2016, Resverlogix presented a poster at the 52nd European Association for the Study of Diabetes (EASD) Annual Meeting. The eVideo presentation can be accessed here: https://youtu.be/dNtA5kPwpZg
August 28th, 2016, Resverlogix supported a PACE-CME educational symposium at the ESC Congress 2016, titled: A Novel Approach for High CV Risk Patients with Diabetes: The Potential of Epigenetics. Expert presenters included: Prof. Kausik Ray, Imperial College, London, UK, Dr. Jorge Plutzky, Brigham and Woman’s Hospital, Harvard Medical School, Boston, MA, and Prof. John Kastelein, Academic Medical Center, Amsterdam, Netherlands. Meeting Highlights, Videos and Slides of the symposium can be accessed HERE.
Resverlogix will be attending several key industry conferences. Website will be udated as presentation opportunities become available. Please note: not all events offer a presentation opportunity and this list is subject to change.
Jan. 9, 2017: 9th Annual Biotech Showcase Conference, San Francisco, CA
Jan. 29-Feb. 2, 2017: Keystone Symposia, Seattle, WA
Feb. 1-3, 2017: 19th Annual Conference on Dialysis Advances in CKD, Las Vegas, NV
Feb. 13-14, 2017: BIO CEO & Investor Conference, New York City, NY
Mar. 9, 2017: BD Boston Conference, Boston MA
Mar. 17-19, 2017: ACC.17, Washington, DC
Mar. 20-22, 2017: BIO-Europe Spring, Barcelona, Spain
Mar. 29-Apr.2, 2017: AD/PD 2017, Vienna, Austria
Resverlogix in the Media
March 29: CTV news filmed on location the RVX lab featuring the Sanofi Biogenius competition.
January 20, 2016: Resverlogix featured in the Life Sciences Report
September 2015: At the 2015 Rodman & Renshaw healthcase conference, Don McCaffrey had a video interview with Stock News Now (SNN).
August 26, 2015: Resverlogix featured in the Life Sciences Report: Disrupting Treatment of Cardiovascular Disease with Epigenetics: Resverlogix CEO Donald McCaffrey.
June 25, 2015: Resverlogix’s Dr. Ewelina Kulikowski has written and published an article for the summer 2015 issue of the European Biopharmaceutical Review (EBR) titled, “New Direction.”
April 22, 2015: Donald McCaffrey, President & CEO on BNN’s Business Day
April 27, 2015: BioCentury: Hepalink gains rights to Resverlogix’s RVX-208 in China.
April 28, 2015: BioWorld Today: Phase III Starting Soon. Resverlogix getting specific: With potential $400M BET, Hepalink licensing accord, by Randy Osborne.
April 28, 2015: Bloomberg Business: Resverlogix in Discussions to Be Bought, by Eric Lam.
April 28, 2015: BioSpace Breaking News: Resverlogix (RVX.TO) CEO Says It’s in Talks With Suitors, After $100M in Q1 Deals, by Riley McDermid.
April 28, 2015: Fierce Biotech: Resverlogix gets a $116M China Drug development deal, stokes buyout buzz, by John Carroll.